Celcuity Shares Fall on Breast Cancer Drug Trial Results
Celcuity shares fell 25 percent after its breast cancer drug data trailed early results. The treatment showed 11.1 months of progression-free survival in patients.
Insights:
Celcuity shares plunged 25% to $92.09 on Tuesday after clinical data for its experimental breast cancer treatment underperformed previous trial results. The sell-off marks the largest one-day decline for the developer as investors reacted to the efficacy of its lead drug candidate, gedatolisib. While the treatment improved patient outcomes compared to current therapies, the results fell short of early-stage benchmarks.
